Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

NCT02324842 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Canagliflozin
DRUG: Liraglutide

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

[object Object]